Generally speaking, data from the literature indicate that the efficacy of different HIF-PHIs in the anemia treatment of CKD patients is comparable, and all HIF-PHIs are equally effective as epoetin α and DA in anemia-correcting in these patients [92,93]. The gene discussed is EPO; the disease is anemia (phenotype).